The role of microglia in neurodegenerative disease

Microglia: Biology, Functions and Roles in Disease

Volumn , Issue , 2012, Pages 93-117

  Su, Paul ^a   Politis, Marios ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Microglia; Neurodegeneration; Neuroinflammation; Neurology; PK11195

Indexed keywords

EID: 84892964983     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (195)

1. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001; 57 (7): 1282-1289.
2. Alliot F, Godin I, Pessac B. Microglia derive from progenitors originating from the yoc sac and which proliferate in the brain. Brain Res. 1999; 117: 145-152.
3. Almer G, Guégan C, Teismann P, Naini A, Rosoklija G, Hays AP, Chen C, Przedborski S. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 2001; 49 (2): 176-185.
4. Aloisi F. Immune function of microglia. Glia. 2001; 36 (2): 165-179.
5. Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis. Assoc Disord. 2000; 14 Suppl 1: 47-53.
6. Armstrong RA, Cairns NJ, Lantos PL. A quantitative study of the pathological lesions in the neocortex and hippocampus of twelve patients with corticobasal degeneration. Exp. Neurol. 2000; 163 (2): 348-356.
7. Babcock AA, Kuziel WA, Rivest S, Owens T. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci 2003; 23 (21): 7922-7930.
8. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity ofmicroglia. Glia 1993; 7:111-118.
9. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord.1998; 13: 221-227.
10. Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, Kreutzberg GW, Brooks DJ, Jones T, Duncan JS. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology 1999; 53 (9): 2199-2203.
11. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123 ( Pt 11): 2321-2337.
12. Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999; 5 (4): 283-286.
13. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr. Opin Neurol. 2002; 15 (3): 239-245.
14. Barnum SR. Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease. Mol. Med 1999; 5 (9): 569-582.
15. Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord. 2010; 16 (1): 57-59.
16. Bate C, Veerhuis R, Eikelenboom P, Williams A. Microglia kill amyloid-beta1-42 damaged neurons by a CD14-dependent process. Neuroreport 2004; 15 (9): 1427-1430.
17. Bauer J, Sminia T, Wouterlood FG, Dijkstra CD. Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis.J. Neurosci. Res. 1994; 38 (4): 365-375.
18. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, Siklos L, McKercher SR, Appel SH. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 2006; 103 (43): 16021-16026.
19. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis.J. Mol. Med. (Berl) 1997; 75 (3): 165-173.
20. Benavides J, Cornu P, Dennis T, Dubois A, Hauw JJ, MacKenzie ET, Sazdovitch V, Scatton B. Imaging of human brain lesions with an omega 3 site radioligand. Ann. Neurol. 1988; 24 (6): 708-712.
21. Bitting L, Naidu A, Cordell B, Murphy GM Jr. Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide. J. Biol. Chem. 1996; 271(27): 16084-16089.
22. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Möller T, Tabrizi SJ. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.J. Exp. Med. 2008; 205 (8): 1869-1877.
23. Bø L, Vedeler CA, Nyland H, Trapp BD, Mørk SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler 2003; 9 (4): 323-331.
24. Bö L, Geurts JJ, van der Valk P, Polman C, Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch. Neurol 2007; 64 (1): 76-80.
25. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312 (5778): 1389-1392.
26. Boillée S, Cleveland DW. Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1.J. Clin. Invest 2008; 118 (2): 474-478.
27. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett 1994; 172 (1-2): 151-154.
28. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J. Neurosci. 2008; 28 (16): 4283-4292.
29. Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. J. Pathol. 2001; 158 (1): 63-73.
30. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J. Neurol. Sci. 2006; 248 (1-2): 255-258.
31. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system.J. Neuropathol. Exp. Neurol. 2002; 61 (11): 1013-1021.
32. Butovsky O, Kunis G, Koronyo-Hamaoui M, Schwartz M. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur. J. Neurosci 2007; 26 (2): 413-416.
33. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358 (9280):461-467.
34. Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. In vivo detection of microglial activation in frontotemporal dementia. Ann. Neurol. 2004; 56 (6): 894-897.
35. Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia: new concepts. Brain Res Rev 2007; 53 (2): 344-354.
36. Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008; 35 (12): 2304-2319.
37. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther 2008; 118 (1): 1-17
38. Choi HB, Khoo C, Ryu JK, van Breemen E, Kim SU, McLarnon JG. Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195. J. Neurochem 2002; 83 (3): 546-555.
39. Choi J, Ifuku M, Noda M, Guilarte TR. Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state. Glia. 2011; 59 (2): 219-230.
40. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 2002; 15 (6):991-998.
41. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann. Neurol. 2002; 52 (5): 650-653.
42. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372 (9648): 1502-1517.
43. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl. J. Med. 2000; 343 (20): 1430-1438.
44. Conway EL, Gundlach AL, Craven JA. Temporal changes in glial fibrillary acidic protein messenger RNA and [3H]PK11195 binding in relation to imidazoline-I2-receptor and alpha 2-adrenoceptor binding in the hippocampus following transient global forebrain ischaemia in the rat. Neuroscience 1998; 82 (3): 805-817.
45. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J. Neuroinflammation 2005; 2: 14.
46. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996; 5 (2): 137-143.
47. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 2007; 6 (7): 2833-2840.
48. Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, Achten E, Slegers G, Dierckx RA, Korf J, De Reuck JL. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur. J. Neurol. 2003; 10 (3): 257-264.
49. De Groot CJ, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, van der Valk P. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p) reactive lesions. Brain 2001;124 (Pt 8): 1635-1645.
50. De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol. Dis. 2010; 37 (3): 630-640.
51. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 2007; 14 (11): 1189-1197.
52. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol. Aging 2001; 22 (6): 1007-1012.
53. Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K. Minocycline 1-year therapy in multiplesystem- atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSAtrial). Mov. Disord. 2010; 25 (1): 97-107.
54. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, Hammers A, Tai YF, Fox N, Kennedy A, Rossor M, Brooks DJ. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 2008; 32 (3): 412-419.
55. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia 2002; 40 (2): 232-239.
56. Elliott JL. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res. Mol. Brain Res. 2001; 95 (1-2): 172-178.
57. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch. Neurol. 1990; 47 (11): 1210-1216.
58. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327 (7407): 128.
59. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, Pitossi FJ. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol. Dis. 2006; 24 (1): 183-193.
60. Ferrer I, Bernet E, Soriano E, del Rio T, Fonseca M. Naturally occurring cell death in the cerebral cortex of the rat and removal of dead cells by transitory phagocytes. Neuroscience 1990; 39 (2): 451-458.
61. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. 2001; 166 (4): 2717-2726.
62. Floden AM, Li S, Combs CK. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J. Neurosci. 2005; 25 (10): 2566-2575.
63. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 1998; 152 (1):307-317.
64. Fujita M, Imaizumi M, Zoghbi SS, Fujimura Y, Farris AG, Suhara T, Hong J, Pike VW, Innis RB. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 2008; 40 (1): 43-52.
65. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem 2002; 81 (6): 1285-1297.
66. Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, Turkheimer F, Good CD, Mathias CJ, Quinn N, Schwarz J, Brooks DJ. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003; 61 (5): 686-689.
67. Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov. Disord 2004; 19 (10): 1221-1226.
68. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006a; 21 (2):404-412.
69. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov. Disord 2006b; 21 (1): 89-93.
70. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995; 20 (3): 269-287. Science. 2005 27; 308 (5726):1314-1318.
71. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain. 1989; 112 (Pt 5):1171-1192.
72. Gilmore CP, Geurts JJ, Evangelou N, Bot JC, van Schijndel RA, Pouwels PJ, Barkhof F, Bö L. Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. Mult. Scler. 2009; 15 (2): 180-188.
73. Graber DJ, Hickey WF, Harris BT. Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J. Neuroinflammation 2010; 7:8.
74. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 1989; 86 (19): 7611-7615.
75. Gulyás B, Halldin C, Sandell J, Karlsson P, Sóvágó J, Kárpáti E, Kiss B, Vas A, Cselényi Z, Farde L. PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol. Scand. 2002; 106 (6): 325-332.
76. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297 (5580): 353-356.
77. Hartlage-Rübsamen M, Lemke R, Schliebs R. Interleukin-1beta, inducible nitric oxide synthase, and nuclear factor-kappaB are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/interferon-gamma injection. J. Neurosci. Res. 1999; 57 (3): 388-398.
78. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44 (11): 2015-2019.
79. Henkel K, Karitzky J, Schmid M, Mader I, Glatting G, Unger JW, Neumaier B, Ludolph AC, Reske SN, Landwehrmeyer GB. Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration. Mov. Disord. 2004a; 19 (7): 817-821.
80. Henkel JS, Engelhardt JI, Siklós L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2004b; 55 (2): 221-235.
81. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hövelmeyer N, Waisman A, Rülicke T, Prinz M, Priller J, Becher B, Aguzzi A. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med. 2005; 11 (2):146-152.
82. Hines DJ, Hines RM, Mulligan SJ, Macvicar BA. Microglia processes block the spread of damage in the brain and require functional chloride channels. Glia 2009; 57 (15): 1610-1618.
83. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000; 290 (5497):1768-1771.
84. Hurley SD, O'Banion MK, Song DD, Arana FS, Olschowka JA, Haber SN. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp. Neurol. 2003; 184 (2): 659-668.
85. Imai F, Suzuki H, Oda J, Ninomiya T, Ono K, Sano H, Sawada M. Neuroprotective effect of exogenous microglia in global brain ischemia. J. Cereb Blood Flow 2007; 27: 488-500.
86. Ikoma Y, Yasuno F, Ito H, Suhara T, Ota M, Toyama H, Fujimura Y, Takano A, Maeda J, Zhang MR, Nakao R, Suzuki K. Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. J. Cereb Blood Flow Metab. 2007; 27 (1): 173-184.
87. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003; 106 (6): 518-526.
88. Ishizawa K, Lin WL, Tiseo P, Honer WG, Davies P, Dickson DW. A qualitative and quantitative study of grumose degeneration in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 2000; 59 (6): 513-524.
89. Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J. Neuropathol. Exp. Neurol. 2001; 60 (6): 647-657.
90. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T. Microglial activation parallels system degeneration in multiple system atrophy. J. Neuropathol. Exp. Neurol. 2004; 63 (1): 43-52.
91. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992; 140 (3): 691-707.
92. Kesselring J. The pathogenesis of multiple sclerosis. Schweiz Med. Wochenschr 1990; 120 (30): 1083-1090.
93. Kida E, Barcikowska M, Niemczewska M. Immunohistochemical study of a case with progressive supranuclear palsy without ophthalmoplegia. Acta Neuropathol. 1992; 83 (3):328-332.
94. Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 2009; 202 (3): 431-439.
95. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar betaamyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 2005; 25 (36): 8240-8249.
96. Kohji T, Matsumoto Y. Coexpression of Fas/FasL and Bax on brain and infiltrating T cells in the central nervous system is closely associated with apoptotic cell death during autoimmune encephalomyelitis. J. Neuroimmunol 2000; 106 (1-2): 165-171.
97. Komori T, Shibata N, Kobayashi M, Sasaki S, Iwata M. Inducible nitric oxide synthase (iNOS)-like immunoreactivity in argyrophilic, tau-positive astrocytes in progressive supranuclear palsy. Acta Neuropathol. 1998; 95 (4): 338-344.
98. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci.1996; 19: 312-318.
99. Krieger C, Perry TL, Ziltener HJ. Amyotrophic lateral sclerosis: interleukin-6 levels in cerebrospinal fluid. Can. J. Neurol. Sci. 1992; 19 (3): 357-359.
100. Kuhle J, Lindberg RL, Regeniter A, Mehling M, Steck AJ, Kappos L, Czaplinski A. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009; 16 (6): 771-774.
101. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128 (Pt 11): 2705-2712.
102. Lacor P, Gandolfo P, Tonon MC, Brault E, Dalibert I, Schumacher M, Benavides J, Ferzaz B. Regulation of the expression of peripheral benzodiazepine receptors and their endogenous ligands during rat sciatic nerve degeneration and regeneration: a role for PBR in neurosteroidogenesis. Brain Res. 1999; 815 (1): 70-80.
103. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine exposure. Ann. Neurol. 1999; 46 (4): 598-605.
104. Lantos PL, Papp MI. Cellular pathology of multiple system atrophy: a review. J. Neurol. Neurosurg Psychiatry 1994; 57 (2): 129-133.
105. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J. Neurol. Sci. 2008; 274 (1-2): 45-47.
106. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeniety in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990; 39: 151-170.
107. LeBlanc AC, Papadopoulos M, Bélair C, Chu W, Crosato M, Powell J, Goodyer CG. Processing of amyloid precursor protein in human primary neuron and astrocyte cultures.J. Neurochem. 1997; 68 (3): 1183-1190.
108. Leung E, Guo L, Bu J, Maloof M, El Khoury J, Geula C. Microglia activation mediates fibrillar amyloid-ß toxicity in the aged primate cortex. Neurobiol. Aging 2011; 32 (3):387-397.
109. Li WW, Setzu A, Zhao C, Franklin RJ. Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a nonimmune model of demyelination. J. Neuroimmunol. 2005; 158 (1-2): 58-66.
110. Li H, Cuzner ML, Newcombe J. Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol Appl. Neurobiol. 1996; 22 (3): 207-215.
111. Li L, Lu J, Tay SS, Moochhala SM, He BP. The function of microglia, either neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro. Brain Res. 2007; 1159: 8-17.
112. Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 2002; 22 (12):4825-4832.
113. Liu Y, Hao W, Dawson A, Liu S, Fassbender K. Expression of amyotrophic lateral sclerosislinked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J. Biol. Chem. 2009; 284 (6): 3691-3699.
114. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat. Rev. Drug Discov. 2008; 7 (11): 909-925.
115. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130 (Pt 4): 1089-1104.
116. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, Aloisi F, Reynolds R. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 2010; 68 (4): 477-493.
117. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 2009; 29 (13): 4252-4262.
118. Marino F, Cattaneo S, Cosentino M, Rasini E, Di Grazia L, Fietta AM, Lecchini S, Frigo G. Diazepam stimulates migration and phagocytosis of human neutrophils: possible contribution of peripheral-type benzodiazepine receptors and intracellular calcium. Pharmacology 2001; 63 (1): 42-49.
119. McCluskey LP, Lampson LA. Local neurochemicals and site specific immune regulation in the CNS.J. Neuropathol. Exp. Neurol. 2000; 59: 177-187.
120. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988a; 38: 1285-1291.
121. McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLADR in neurological disease. Acta Neuropathol 1988b; 76 (6): 550-557.
122. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996; 15:5647-5658.
123. Messmer K, Reynolds GP. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci. Lett 1998; 241(1): 53-56.
124. Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions:Effects of oligomeric and fibrillar amyloid-beta. J. Neuroimmunol. 2009; 210 (1-2): 3-12.
125. Mirra SS, Hyman BT. Aging and dementia. In: Graham DI, Lantos PL, eds. Greenfield's neuropathology. Vol 2. London: Arnold, 2002: 195-271.
126. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factoralpha (TNF- alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett 1994; 165: 208-210.
127. Munoz DG, Dickson DW, Bergeron, eds. The neuropathology and biochemistry of frontotemporal dementia. Ann. Neurol. 2003; 54 (Suppl 15): 24-28.
128. Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience 2009; 158 (3): 1030-1038.
129. Neumann J, Gunzer M, Gutzeit HO, Ullrich O, Reymann KG, Dinkel K. Microglia cells provide neuroprotection after ischemia. FASEB J; 2006; 20: 714-716.
130. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51 (6):1546-1554.
131. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308 (5726): 1314-1318.
132. Oh U, Fujita M, Ikonomidou VN, Evangelou IE, Matsuura E, Harberts E, Fujimura Y, Richert ND, Ohayon J, Pike VW, Zhang Y, Zoghbi SS, Innis RB, Jacobson S. Translocator protein PET imaging for glial activation in multiple sclerosis. J. Neuroimmune Pharmacol. 2011; 6 (3): 354-361.
133. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, Brooks DJ. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009a; 72 (1): 56-62.
134. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009b; 73 (10): 754-760.
135. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005; 57 (2): 168-175.
136. Papadopoulos V, Amri H, Boujrad N, Cascio C, Culty M, Garnier M, Hardwick M, Li H, Vidic B, Brown AS, Reversa JL, Bernassau JM, Drieu K. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids. 1997; 62 (1): 21-28.
137. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci.2006; 27 (8): 402-409.
138. Paulus W, Bancher C, Jellinger K. Microglial reaction in Pick's disease. Neurosci. Lett 1993; 161: 89-92.
139. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006; 66 (11): 1638-1643.
140. Pender MP, Rist MJ. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia 2001; 36 (2): 137-144.
141. Peress NS, Fleit HB, Perillo E, Kuljis R, Pezzullo C. Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease. J. Neuroimmunol. 1993; 48 (1):71-79.
142. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001; 50 (3):389-400.
143. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, Cuzner ML, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002; 125 (Pt 7): 1462-1473.
144. Pike VW, Halldin C, Crouzel C, Barré L, Nutt DJ, Osman S, Shah F, Turton DR, Waters SL. Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites--current status. Nucl. Med. Biol. 1993;20 (4): 503-525.
145. Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008; 131 (Pt 11): 2860-2869.
146. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum. Brain Mapp 2011; 32 (2): 258-270.
147. Politis M, Gianneti P, Su P, Turkheimer F, Keihaninejad S, Wu K, Waldman A, Malik O, Matthews PM, Reynolds R, Nicholas R, Piccini P. Increased PK11195 PET binding in the cortex of MS patients correlates with disability. Neurology; in press.
148. Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett 2000; 287 (3): 211-214.
149. Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol. 2009; 117 (1): 63-73.
150. Pramatarova A, Laganière J, Roussel J, Brisebois K, Rouleau GA. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci.2001; 21 (10): 3369-3374.
151. Raine CS. Multiple sclerosis: immune system molecule ex- pression in the central nervous system. J. Neuropathol. Exp. Neurol. 1994; 53: 328-337.
152. Raivich G, Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res. Brain Res. Rev. 2004; 46 (3): 261-281.
153. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol.2009; 27: 119-145.
154. Rao SM. Neuropsychology of multiple sclerosis. Curr. Opin. Neurol. 1995; 8 (3): 216-220.
155. Rasmussen S, Wang Y, Kivisäkk P, Bronson RT, Meyer M, Imitola J, Khoury SJ. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing--remitting experimental autoimmune encephalomyelitis. Brain 2007; 130 (Pt 11): 2816-2829.
156. Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch. Neurol. 1968; 18 (1): 20-33.
157. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362 (6415): 59-62.
158. Sanagi T, Yuasa S, Nakamura Y, Suzuki E, Aoki M, Warita H, Itoyama Y, Uchino S, Kohsaka S, Ohsawa K. Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2010; 88 (12): 2736-2746.
159. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One. 2010; 5 (1).
160. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 2001; 60: 161-172.
161. Sargsyan SA, Blackburn DJ, Barber SC, Monk PN, Shaw PJ. Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1. Neuroreport 2009; 20 (16): 1450-1455.
162. Scarf AM, Ittner LM, Kassiou M. The translocator protein (18 kDa): central nervous system disease and drug design. J. Med. Chem. 2009; 52 (3): 581-592.
163. Schilling M, Besselmann M, Leonhard C, Mueller M, Ringelstein EB, Kiefer R. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp. Neurol. 2003; 183 (1): 25-33.
164. Schwarz SC, Seufferlein T, Liptay S, Schmid RM, Kasischke K, Foster OJ, Daniel S, Schwarz J. Microglial activation in multiple system atrophy: a potential role for NFkappaB/ rel proteins. Neuroreport 1998; 9 (13): 3029-3032.
165. Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J. Neurol. Sci. 1998; 154 (2): 194-199.
166. Setzu A, Lathia JD, Zhao C, Wells K, Rao MS, Ffrench-Constant C, Franklin RJ. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia 2006; 54 (4): 297-303.
167. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S, Kobayashi M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001; 917 (1): 97-104.
168. Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 1999; 159 (2): 362-376.
169. Sitte HH, Wanschitz J, Budka H, Berger ML. Autoradiography with [3H]PK11195 of spinal tract degeneration in amyotrophic lateral sclerosis. Acta Neuropathol. 2001; 101 (2): 75-78.
170. Slavik JM, Hutchcroft JE, Bierer BE. CD28/ CTLA-4 and CD80/ CD86 families: signaling and function. Immunol. Res. 1999; 19: 1-24.
171. Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125 (Pt 1): 75-85.
172. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 1999; 154 (6): 1673-1684.
173. Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy:implications for multiple system atrophy. Mov. Disord. 2007; 22 (15): 2196-2203.
174. Stephenson DT, Schober DA, Smalstig EB, Mincy RE, Gehlert DR, Clemens JA. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J. Neurosci. 1995; 15 (7 Pt 2): 5263-5274.
175. Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal. 2009; 11 (9): 2151-2166.
176. Suzumura A, Sawada M, Marunouchi T. Selective induction of interleukin-6 in mouse microglia by granulocyte-macrophage colony-stimulating factor. Brain Res. 1996; 713 (1-2): 192-198.
177. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog. Neurobiol. 1999 57 (6): 563-581.
178. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130 (Pt 7):1759-1766.
179. Takami S, Nishikawa H, Minami M, Nishiyori A, Sato M, Akaike A, Satoh M. Induction of macrophage inflammatory protein MIP-1alpha mRNA on glial cells after focal cerebral ischemia in the rat. Neurosci. Lett 1997; 227 (3): 173-176.
180. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, Leigh PN, Banati RB. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004; 15 (3): 601-609.
181. Turner MR, Gerhard A, Al-Chalabi A, Shaw CE, Hughes RA, Banati RB, Brooks DJ, Leigh PN. Mills' and other isolated upper motor neurone syndromes: in vivo study with 11C- (R)-PK11195 PET. J. Neurol. Neurosurg Psychiatry 2005; 76 (6): 871-874.
182. Uchihara T, Ikeda K, Tsuchiya K. Pick body disease and Pick syndrome. Neuropathology 2003; 23: 318-326.
183. Van Rossum D, Hanisch UK. Microglia. Metab. Brain Dis. 2004 19: 393-411.
184. Vas A, Shchukin Y, Karrenbauer VD, Cselényi Z, Kostulas K, Hillert J, Savic I, Takano A, Halldin C, Gulyás B. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. J. Neurol. Sci. 2008; 264 (1-2): 9-17.
185. Veenman L, Papadopoulos V, Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr. Pharm Des. 2007; 13 (23): 2385-2405.
186. Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, Apte UM, Wiley CA. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol. Aging 2009; 30 (8): 1217-1226.
187. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70 (19): 1672-1677.
188. Vonsattel JP, DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998; 57 (5):369-384.
189. Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, Antel JP. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neurosci. Res. 1997; 50 (2): 345-353.
190. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci. 1; 29 (13): 3974-3980.
191. Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol. Sci. 2007; 28 (10): 536-543.
192. Weydt P, Yuen EC, Ransom BR, Möller T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 2004; 48 (2): 179-182.
193. Wilms H, Claasen J, Röhl C, Sievers J, Deuschl G, Lucius R. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol. Dis. 2003; 14 (3): 417-424.
194. Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, Wakuda T, Sugihara G, Takebayashi K, Suda S, Iwata Y, Ueki T, Tsuchiya KJ, Suzuki K, Nakamura K, Ouchi Y. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2011; 38 (2):343-351.
195. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005; 19 (6): 533-542.